IMMP's logo.
Ticker Symbol: IMMP

Immutep Limited - ADR

$4.07 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: Australia Currency: USD Asset Type: ADR CIK:0001506184

Company Profile

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: Plaza Building
CEO: Marc Voigt
Tags:
  • Health Technology
  • Biotechnology

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.80
Change: -$0.04 ( -2.17%)
Days Range: $1.78 - $1.87
Beta: -
52wk. High: $3.90
52wk. Low: $1.50
Ytd. Change 2.97%
50 Day Moving Average: $1.90
200 Day Moving Average: $1.94
Shares Outstanding: 118883456

Valuation

Market Cap: 21.4B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A